Elevidys access in India: the CDSCO Rule 36 named-patient pathway
How Indian families with a child diagnosed with Duchenne muscular dystrophy access Elevidys (delandistrogene moxeparvovec), the AAV-based DMD gene therapy, through the CDSCO Rule 36 personal-import framework and qualified tertiary pediatric neurology centers.
Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.
Quick orientation
Elevidys (delandistrogene moxeparvovec-rokl) is an AAVrh74-based one-time gene therapy delivering a transgene encoding micro-dystrophin, approved by the US FDA on 22 June 2023 for ambulatory pediatric patients aged 4 through 5 with Duchenne muscular dystrophy, and expanded on 20 June 2024 to ambulatory patients 4 years and older and non-ambulatory patients 4 years and older with a confirmed DMD mutation. It is the first and only gene therapy approved for DMD. The drug is not currently registered with the Central Drugs Standard Control Organization (CDSCO), so Indian families reach it through the Rule 36 personal-import framework with Form 12A application and Form 12B permit, or through institutional Compassionate Use at major academic centers. Reserve Meds coordinates the US-side sourcing, frozen cold-chain logistics, and the documentation kit the treating pediatric neurology team needs to file with CDSCO.
Reserved for you.
Why Indian families need Elevidys through the named-patient pathway
India carries one of the largest absolute populations of Duchenne muscular dystrophy patients in the world given the country's demographic scale. Prevalence sits at the global 1 in 3,500 to 1 in 5,000 male birth range; in absolute terms, the Indian DMD cohort is in the tens of thousands. The country's tertiary pediatric neurology infrastructure is meaningful: AIIMS New Delhi (a designated Centre of Excellence under the National Policy for Rare Diseases), NIMHANS Bangalore, the Christian Medical College Vellore, Sankara Nethralaya and SRMC Chennai, KEM Hospital Mumbai, B.J. Wadia Hospital for Children Mumbai, the Apollo Hospitals network, Fortis Memorial Research Institute Gurgaon, Medanta The Medicity Gurgaon, Kokilaben Dhirubhai Ambani Hospital Mumbai, and Manipal Hospitals Bangalore. The Dystrophy Annihilation Research Trust (DART) Bangalore and the Muscular Dystrophy Foundation India have driven significant patient-advocacy-led genetic confirmation capability over the past decade.
The access gap for Elevidys in India has four layers. First, regulatory: Sarepta has not filed Elevidys with CDSCO for commercial registration. Second, certified-center capability: AAV gene therapy infusion requires a pediatric institution with infusion suite, post-infusion ICU backup, validated minus 60 degrees Celsius storage, and immunomonitoring infrastructure; the count of qualified Indian sites is narrow. Third, eligibility gating: anti-AAVrh74 antibody titer must be below the FDA-labeled threshold, the patient must have a confirmed DMD mutation by next-generation sequencing or MLPA, and the family must accept the boxed-warning context for serious immune-mediated myositis. Fourth, payer reality: at USD 3.2 million list price (approximately INR 26.5 crore at the May 2026 INR 83 rate), no Indian public scheme or private insurer reimburses at this list level. The National Policy for Rare Diseases 2021 financial assistance ceiling under Rashtriya Arogya Nidhi is INR 50 lakh per patient, which is meaningful but materially below the all-in cost. Cash-pay funded through family resources, often supplemented by overseas Indian family members, is the operating reality.
The clinical case is time-sensitive: disease-modifying benefit in DMD is greatest before substantial muscle loss has occurred. Indian families who reach us are typically working against an active disease trajectory after years of corticosteroids and supportive care. Exon-skipping therapies (eteplirsen, viltolarsen, golodirsen, casimersen) are not consistently locally available in India, which sharpens the case for the AAV gene therapy where the patient is eligible.
The CDSCO Rule 36 named-patient pathway for Elevidys
The legal foundation for personal import of an unregistered or non-stocked medicine into India is Rule 36 of the Drugs and Cosmetics Rules 1945. Rule 36 permits the import of a small quantity of a drug, whose import would otherwise be prohibited under Section 10 of the Drugs and Cosmetics Act 1940, for the exclusive personal use of a named patient. Form 12A is the application for the permit. Form 12B is the permit itself, issued by the office of the Drugs Controller General of India (DCGI) at FDA Bhawan, Kotla Road, New Delhi, or by designated CDSCO Port Offices. The application is accompanied by a prescription from a Registered Medical Practitioner (RMP) showing the RMP's National Medical Commission (NMC) registration number and the quantity required for treatment.
For institutional Compassionate Use of drugs not approved or not locally stocked, the parallel pathway is the Compassionate Use application to the DCGI by a government hospital, a registered medical practitioner, a pharmaceutical company, or the patient. Severe pediatric DMD progressing despite standard corticosteroid therapy fits the life-threatening condition framing. AIIMS New Delhi (a designated Centre of Excellence under the National Policy for Rare Diseases), the major academic medical centers, and the largest private referral hospitals have established Compassionate Use workflow for advanced rare disease cases.
For Elevidys specifically, the clinical-justification angle that anchors the application is genetic confirmation plus institutional gene-therapy readiness. The strongest applications document: a confirmed DMD diagnosis with the specific dystrophin gene mutation reported by a named genetics laboratory (NGS report with the deletion, duplication, or point mutation specified); the patient's age (4 years or older) and ambulatory or non-ambulatory status; the baseline NSAA score for ambulatory cases, or upper-limb and respiratory measures for non-ambulatory cases; the anti-AAVrh74 binding antibody titer; the immunosuppression plan; and the receiving institution's gene therapy infusion capability. Approval timelines for routine cases at major institutions run 2 to 4 weeks for Form 12B issuance with complete documentation; first-time gene-therapy imports can extend to 6 to 10 weeks given the limited Indian institutional precedent.
Where Elevidys gets dispensed in India
The treating-center map for Elevidys in India is narrow because of the AAV gene therapy infusion capability requirement. The institutions most likely to handle an Indian Elevidys case are AIIMS New Delhi (designated Centre of Excellence under the National Policy for Rare Diseases, with the country's deepest rare-disease bench), NIMHANS Bangalore (the country's flagship neurosciences institute), the Christian Medical College (CMC) Vellore, KEM Hospital and B.J. Wadia Hospital for Children Mumbai (with a pediatric neurology footprint), Apollo Hospitals (Chennai flagship, Delhi, Bangalore, Hyderabad), Fortis Memorial Research Institute Gurgaon, Medanta The Medicity Gurgaon, Kokilaben Dhirubhai Ambani Hospital Mumbai, MGM Healthcare Chennai, and Manipal Hospitals Bangalore. CMC Vellore and NIMHANS Bangalore have particular depth in muscle biopsy, neurogenetics, and pediatric muscular dystrophy.
The dispensing facility must hold validated frozen storage at minus 60 degrees Celsius or colder, gene therapy infusion suite capability, pediatric critical care backup, and laboratory turnaround for the post-infusion monitoring schedule including weekly creatine kinase, troponin, AST, ALT, total bilirubin, and platelet count for the first 90 days. The receiving institution carries the peri-infusion corticosteroid course (oral prednisone 1 mg/kg/day or equivalent starting one day before infusion, continuing for at least 60 days, with taper based on clinical and laboratory parameters). For Indian families where the originating consultation is at a regional hospital outside the major metros, the practical pathway routes the case to one of the tertiary centers for the infusion itself.
Real cost picture for Elevidys in India
US wholesale acquisition cost for Elevidys is approximately USD 3.2 million per single-dose treatment course, the highest list price for any FDA-approved gene therapy as of this page date. At the prevailing USD/INR rate (1 USD = approximately 83 INR in May 2026), the cell-product price converts to approximately INR 26.5 crore. This is a one-time price and reflects the entire therapy.
International logistics for the frozen shipper from the Sarepta manufacturing facility to the receiving Indian pediatric center add a defined surcharge in the USD 6,000 to USD 18,000 range (approximately INR 5 to 15 lakh), with customs pre-clearance at the appropriate CDSCO Port Office handled in parallel to preserve the validated shipping window. The receiving institution's procedural and inpatient costs (gene therapy infusion suite, peri-infusion corticosteroid course, post-infusion monitoring labs across the first three months, pediatric critical care standby) are the institution's line items, not Reserve Meds'. Reserve Meds' concierge fee is itemised separately on every firm quote.
On the payer side, Indian payer behavior at the USD 3.2 million price point is restrictive. Star Health, HDFC ERGO, ICICI Lombard, Niva Bupa, and Tata AIG each assess pediatric gene therapy case by case, with most commercial plans falling materially short of coverage. CGHS provides for life-saving medicines not in the standard formulary to be considered by an Expert Committee under Special DG (DGHS) for central government employees and pensioners, with stricter constraints for drugs not approved by CDSCO. The National Policy for Rare Diseases 2021 financial assistance ceiling under Rashtriya Arogya Nidhi is INR 50 lakh per patient, which is meaningful but materially below the all-in Elevidys cost. The Union Budget 2026-27 expanded the list of life-saving and rare-disease drugs eligible for customs duty exemption; HSN code applicability for any specific shipment is confirmed at the documentation stage. Cash-pay funded through family resources, often supplemented by overseas Indian family members in the GCC, UK, North America, and Australia, is the dominant operating posture. We do not promise coverage from any insurer or scheme.
Typical timeline for Elevidys in India
CDSCO Form 12A filing to Form 12B issue runs one to two business days for routine personal-import applications with complete documentation; first-time gene-therapy imports at any given Indian institution can extend to six to ten weeks given the limited institutional precedent. The frozen shipper logistics and customs pre-clearance at the CDSCO Port Office run in parallel with the regulatory filing. End-to-end from family decision to infusion day, the typical achievable window is eight to fourteen weeks. The anti-AAVrh74 antibody titer test result is the earliest gating event; if the titer is above the FDA-labeled threshold, the case pauses for retest consideration before the frozen shipper is staged. The peri-infusion corticosteroid course starts one day before infusion; the post-infusion monitoring window extends three months actively and longer for the structured pharmacovigilance follow-up.
What your physician needs to provide
For an Indian pediatric neurologist prescribing Elevidys through the CDSCO Rule 36 pathway, the clinical justification letter is the cornerstone of the application. The letter, signed by a Registered Medical Practitioner holding an active National Medical Commission registration number with state council registration where required, documents the DMD diagnosis with the specific dystrophin gene mutation reported by a named genetics laboratory, the patient's age (4 years or older), ambulatory or non-ambulatory status, baseline functional assessment (NSAA for ambulatory; Performance of the Upper Limb scale and respiratory measures for non-ambulatory), the anti-AAVrh74 binding antibody titer result with the validated assay named, the immunosuppression plan, and the dosing at 1.33 x 10^14 vg/kg delivered as a single intravenous infusion.
The monitoring plan covers weekly creatine kinase, troponin-I, AST, ALT, total bilirubin, and platelet count for the first 90 days, with the boxed-warning vigilance for serious immune-mediated myositis. The treating physician's NMC registration number, the dispensing facility's Drug License under Schedule M, and the institutional pharmacy in charge of dispensing complete the package. Adverse event reporting through the Indian Pharmacopoeia Commission's Pharmacovigilance Programme of India (PvPI) is referenced in the documentation kit; reporting obligations remain with the prescribing physician and the institution.
Common questions about Elevidys in India
Is Elevidys registered in India? Not at this page date. Sarepta has not filed Elevidys with CDSCO for commercial registration. Access for Indian families runs through the CDSCO Rule 36 personal-import pathway or institutional Compassionate Use with US-source supply under DSCSA chain-of-custody documentation.
My son is 3 years old. Can he still receive Elevidys? The FDA label is patients 4 years and older. Under-4 cases are off-label and require a separate clinical justification not part of the standard Rule 36 route. The treating pediatric neurology team makes the final eligibility call.
What if the anti-AAVrh74 antibody titer is too high? A titer above the FDA-labeled threshold by the validated assay is an eligibility exclusion at the time of testing. The treating pediatric neurology team determines retest cadence; in some cases titers can fall over time. If the titer remains elevated, the case typically pivots to ongoing corticosteroid therapy and supportive care.
Will Star Health, HDFC ERGO, ICICI Lombard, Niva Bupa, or Tata AIG cover the USD 3.2 million list price? None of the major Indian private insurers reimburse a multi-million-dollar one-time gene therapy as a standard line item. Reserve Meds provides documentation that lets a payer evaluate; the claim itself is filed by the patient or institution. The Rashtriya Arogya Nidhi ceiling under NPRD 2021 is INR 50 lakh per patient, which is meaningful but well below the all-in Elevidys cost. Cash-pay is the default operating posture.
Will CGHS or the National Policy for Rare Diseases scheme cover this? CGHS provides for life-saving medicines not in the standard formulary to be considered case-by-case by an Expert Committee under Special DG (DGHS), with stricter constraints for drugs not approved by CDSCO. The NPRD 2021 financial assistance ceiling is INR 50 lakh per patient. Check eligibility with your scheme administrator before assuming coverage.
Can the medicine be administered outside the major metros? The dispensing facility must hold gene therapy infusion capability, pediatric critical care backup, and validated minus 60 degrees Celsius storage. In practice this concentrates the administration at AIIMS, NIMHANS, CMC Vellore, KEM and B.J. Wadia Mumbai, Apollo flagship sites, Fortis Memorial, Medanta, Kokilaben, MGM, and Manipal. Pre- and post-infusion follow-up can be coordinated with the family's home-region neurologist in coordination with the originating institution.
How does Elevidys interact with corticosteroids my son is already on? Most DMD patients in India are already on long-term prednisone or deflazacort therapy. The peri-infusion corticosteroid plan layers on top of or transitions from the existing regimen, with the treating neurologist managing the overall steroid exposure. The decision sequence rests with the treating team.
What is the boxed-warning serious immune-mediated myositis? Severe muscle weakness, severe creatine kinase elevation, and troponin elevation in the first three months after infusion are the labeled risk for serious immune-mediated myositis. The receiving institution carries the weekly laboratory monitoring through the structured window, with corticosteroid escalation, IVIG, and other immunomodulation as the clinical response pathway. The family receives clear instructions on warning signs and a direct phone line to the institution between visits.
Where Reserve Meds fits in Elevidys cases
Reserve Meds is a US-based concierge coordinator. We do not replace your pediatric neurologist, we do not replace CDSCO, and we do not replace the receiving institution's gene therapy and critical care infrastructure. For Elevidys specifically, we orchestrate the US-side sourcing through Sarepta's qualified channel under DSCSA chain-of-custody, build the documentation kit your physician submits for Form 12A or institutional Compassionate Use, coordinate frozen cold-chain logistics with continuous temperature logging into India, pre-stage customs clearance at the CDSCO Port Office in parallel with regulatory filing, manage the multi-currency funding workflow with overseas Indian family wires, and assign a single named coordinator through the case. The clinical decisions remain with the treating pediatric neurology and gene therapy team; the regulatory authority remains CDSCO; the gene therapy delivery remains with the qualified Indian institution.
Next step
If your pediatric neurologist has diagnosed DMD in your son and you are weighing the Elevidys cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.